Peripheral Artery Disease Clinical Trial
— Smart MOVEOfficial title:
Enhanced Home-Based Exercise Therapy for Peripheral Arterial Disease Through Mobile Health and Remote Monitoring
Peripheral artery disease (PAD) is a highly prevalent condition affecting up to 10% of Veterans that leads to loss of walking ability and increased risk of amputation. Veterans have limited access to supervised exercise therapy, a facility-based program proven to improve walking ability in PAD, which is poorly attended due to the inconvenience and cost of attending a 12-week program with multiple weekly sessions. This CDA-2 application will investigate the feasibility of home-based exercise therapy (HBET) delivered using mobile health (mHealth) technologies in Veterans with symptomatic PAD. We will partner with the MOVE! program to deliver HBET through group behavioral coaching and a novel wearable activity monitor in a newly proposed program called Smart MOVE!. There is a clear need to provide effective and convenient alternatives to supervised exercise for Veterans with PAD. This study will provide evidence to proceed with Smart MOVE!, a much-needed patient-centered rehabilitation program for Veterans with PAD.
| Status | Recruiting |
| Enrollment | 75 |
| Est. completion date | September 30, 2026 |
| Est. primary completion date | March 31, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 40 Years and older |
| Eligibility | Inclusion Criteria: - Age >40 years - Eligible Veteran status - Clinically stable intermittent claudication ( 2 months of Rutherford Class II symptoms, no evidence of chronic limb-threatening ischemia) - Established PAD diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging) - Access to safe location to perform walking exercises Exclusion Criteria: - Above or below knee amputation - critical limb ischemia (rest pain or tissue loss including ulceration or gangrene) - inability to walk without a walker - wheelchair confinement - non-English speaking - significant visual impairment that interferes with walking activity - hearing impairment that interferes with full study participation - unable or unwilling to return to the medical center at the expected visit frequency or unable or unwilling to use the technology required for the intervention - Individuals whose walking is limited by a condition other than PAD - Any active cardiac condition including unstable angina - unstable atrial or ventricular arrhythmias - high-grade heart block without a pacemaker - active myopericarditis - recent venous thromboembolism - or recent abnormal baseline stress test suggesting ischemia - other high-risk findings (e.g., drop of systolic blood > 20 mmHg with exercise) - Presence of Class III NYHA heart failure or CCS III angina. - Major surgery including lower extremity revascularization or orthopedic surgery during the preceding three months or anticipated in the next nine months - Major medical illness including lung disease requiring continuous oxygen (patients wearing nighttime oxygen only may still qualify) - neurodegenerative disorders such as Parkinson's Disease that impair walking ability - cancer requiring treatment in the past 2 years (with exception for non-melanoma skin cancer or if they received treatment for early-stage cancer with an excellent overall prognosis) - Heart attack, stroke, or coronary artery bypass surgery in the preceding 3 months - Mental health illness that may interfere with the ability to consent and/or participate in the study, including mini-mental status examination score <24 - dementia - active psychiatric disorder such as schizophrenia or bipolar disorder - history of suicidal or homicidal ideation in the preceding six months - history of suicidal attempts in the preceding 12 months - history of active substance use in the preceding six months that would interfere with study participation (as determined by their primary care or mental health provider) - Subjects endorsing SI or HI may be eligible for continued participation with monitoring if approved by their primary mental health provider - Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention - Currently enrolled in another clinical trial or structured exercise program (i.e., cardiac rehabilitation) - Deemed to be poorly suited for the study or the study intervention at the discretion of the PI or study staff |
| Country | Name | City | State |
|---|---|---|---|
| United States | Atlanta VA Medical and Rehab Center, Decatur, GA | Decatur | Georgia |
| Lead Sponsor | Collaborator |
|---|---|
| VA Office of Research and Development | LifeQ |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 6-minute walk test | The 6MWT is a well-validated measure of functional capacity and increasingly recognized as a meaningful outcome measure in PAD. Participants will be asked to walk back and forth along a 100-foot hallway for six minutes using standard methods and have their total distance recorded | 90 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
| Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
| Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
| Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
| Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
| Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
| Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
| Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
| Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
| Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
| Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries
|
N/A | |
| Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
| Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
| Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
| Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
| Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
| Completed |
NCT02228564 -
BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
| Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
| Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
| Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A |